Freshfields advised Luxinva on cash acquisition of Dechra Pharmaceuticals
The all-cash deal was worth £4.46 billion
Freshfields advised Luxinva on cash acquisition of Dechra Pharmaceuticals The all-cash deal was worth £4.46 billion Freshfields Bruckhaus Deringer has advised Luxinva, a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA) and managed by its private equities department, on the recommended acquisition of Dechra Pharmaceuticals PLC. Dechra is a global...
Freshfields advised Luxinva on cash acquisition of Dechra Pharmaceuticals
The all-cash deal was worth £4.46 billion
Freshfields Bruckhaus Deringer has advised Luxinva, a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA) and managed by its private equities department, on the recommended acquisition of Dechra Pharmaceuticals PLC.
Dechra is a global veterinary pharmaceuticals and related products business, listed on the London Stock Exchange.
The consortium is led by Swedish investment firm EQT with Luxinva as a co-investor.
A senior cross-border, cross-practice team at Freshfields Bruckhaus Deringer was led by regional Managing Partner for MENA Michael Hilton (Abu Dhabi) and partner Stephen Hewes (London), with the support of Senior Associate Cheree Gemmell (Abu Dhabi) and Associate Nikki Willson (London).
The antitrust advice was given by Partner Rafique Bachour (Brussels) and tax aspects assistance was provided by Partner Peter Clements (London).